Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

The ying and yang of rifampicin

Nature Medicine volume 4, pages 14–15 (1998)Cite this article

The binding of rifampicin to the human glucocorticoid receptor explains how this antibiotic exerts its immunosuppressive effects (pages 92–96).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mitchison, D.A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219–226 (1985).

    Article  CAS  Google Scholar 

  2. Bloom, B.R. & Murray, C.J.L., Commentary on a re-emergent killer. Science 257, 1055–1064 (1992).

    Article  CAS  Google Scholar 

  3. Grosset, J. & Leventis, S. Adverse effects of rifampin. Rev. Infect. Dis. 5, Supplement 3, S440–446 (1983).

    Article  CAS  Google Scholar 

  4. Calleja, C., Pascussi, J.M., Mani, J.C., Maurel, P. & Vilarem, M.J. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nature Med. 4, 92–96 (1998).

    Article  CAS  Google Scholar 

  5. Miller, L.P., Crawford, J.T. & Shinnick, T.M. The rpoB gene of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 805–811 (1994).

    Article  CAS  Google Scholar 

  6. Zilly, W., Breimer, D.D. & Richter, E. Induction of drug metabolism in man after rifampicin treatment measured by incresed hexobarbital and tolbutamide clearance. Eur. J. Gin. Pharmacol. 9, 219–227 (1977).

    Google Scholar 

  7. Barry, M., Gibbons, S., Back, D. & Mulcahy, F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clinical Pharmacokinetics 32, 194–209 (1997).

    Article  CAS  Google Scholar 

  8. Heifets, L.B., Lindholm-Levy, P.J. & Flory, M.A. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141, 626–630 (1990).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, 10461, USA

    John S. Blanchard

Authors
  1. John S. Blanchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blanchard, J. The ying and yang of rifampicin. Nat Med 4, 14–15 (1998). https://doi.org/10.1038/nm0198-014

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0198-014

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing